Preoperative Biomarkers and Survival in Chinese Breast Cancer Patients with HIV: A Propensity-Score-Matched-Cohort Study

Background: China initiated its national free antiretroviral therapy program in 2004 and saw a dramatic decline in mortality among the population with HIV. However, the morbidity of non-AIDS-defining cancers such as breast cancer is steadily growing as life expectancy improves. The aim of this study was to investigate the clinical characteristics and prognosis of breast cancer patients with HIV in China. Materials and methods: Data from 21 breast cancer patients with HIV and 396 breast cancer patients without HIV treated at the Shanghai public health clinical center from 2014–2022 was collected. After propensity score matching, 21 paired patients in the two groups were obtained and compared. The optimal cut-off value of preoperative biomarkers for recurrence was determined via maximally selected log-rank statistics. Preoperative biomarkers were categorized into high and low groups, based on the best cut-off values and compared using Kaplan–Meier survival curves and the log-rank test. The Cox proportional hazards regression model was used to perform univariate and multivariate analyses. Results: The median follow-up time was 38 months (IQR: 20–68 months) for the propensity-score-matching cohort. The progression-free survival at 1, 2 and 3 years for patients with and without HIV were 74.51%, 67.74%, and 37.63% and 95.24%, 95.24%, and 90.48%, respectively. The overall survival for patients with HIV at 1, 2 and 3 years were 94.44%, 76.74%, and 42.63%. After multivariate analysis, Only HIV status (hazard ratios (HRs) = 6.83, 95% [confidence intervals (CI)] 1.22–38.12) were associated with progression-free survival. Based on the best cut-off value, CD8 showed discriminative value for overall survival (p = 0.04), whereas four variables, the lymphocyte-to-monocyte ratio (p = 0.02), platelet-to-lymphocyte ratio (p = 0.03), CD3 (p = 0.01) and CD8 (p < 0.01) were suggested be significant for progression-free survival. The univariate analysis suggested that CD3 (HRs = 0.10, 95% [CI] 0.01–0.90) and lymphocyte-to-monocyte ratio (HRs = 0.22, 95% [CI] 0.05–0.93) were identified as significant predictors for progression-free survival. Conclusion: In this study, breast cancer in patients with HIV in China reflected a more aggressive nature with a more advanced diagnostic stage and worse prognosis. Moreover, preoperative immune and inflammatory biomarkers might play a role in the prognosis of breast cancer patients with HIV.

[1]  J. Jacobson,et al.  Breast cancer survival in women living with HIV. , 2022, The lancet. HIV.

[2]  L. Wyrwicz,et al.  Correlation between Lymphocyte-to-Monocyte Ratio (LMR), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Tumor-Infiltrating Lymphocytes (TILs) in Left-Sided Colorectal Cancer Patients , 2022, Biology.

[3]  Shaotong Zhang,et al.  Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio and Development of a Nomogram in Breast Cancer Patients , 2021, Frontiers in Oncology.

[4]  Y. Shin,et al.  Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2–CCR2 signaling , 2021, Laboratory Investigation.

[5]  L. Shen,et al.  Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor , 2021, Frontiers in Oncology.

[6]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[7]  L. Jia,et al.  Pretreatment lymphocyte‐to‐monocyte ratios predict AIDS‐related diffuse large B‐cell lymphoma overall survival , 2020, Journal of medical virology.

[8]  P. Russo,et al.  The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. , 2019, Urologic oncology.

[9]  A. Jemal,et al.  Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base , 2019, Cancer.

[10]  R. Zheng,et al.  [Report of cancer epidemiology in China, 2015]. , 2019, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[11]  K. Ruxrungtham,et al.  CD4/CD8 ratio normalization rates and low ratio as prognostic marker for non-AIDS defining events among long-term virologically suppressed people living with HIV , 2018, AIDS Research and Therapy.

[12]  Chengzhong Ye,et al.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis , 2018, Nature Medicine.

[13]  R. Yarchoan,et al.  HIV‐Associated Cancers and Related Diseases , 2018, The New England journal of medicine.

[14]  S. Grover,et al.  Breast Cancer and HIV in Sub-Saharan Africa: A Complex Relationship , 2017, Journal of global oncology.

[15]  R. Storey,et al.  The role of platelets in inflammation , 2015, Thrombosis and Haemostasis.

[16]  F. Donato,et al.  Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study , 2015, Journal of acquired immune deficiency syndromes.

[17]  J. Hurley,et al.  Clinical outcomes in breast cancer patients with HIV/AIDS: a retrospective study , 2015, Breast Cancer Research and Treatment.

[18]  C. Tsoukas,et al.  Delay in cART Initiation Results in Persistent Immune Dysregulation and Poor Recovery of T-Cell Phenotype Despite a Decade of Successful HIV Suppression , 2014, PloS one.

[19]  R. Phillips,et al.  HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression , 2014, AIDS.

[20]  R. Konwar,et al.  Presence of CD3+ tumor infiltrating lymphocytes is significantly associated with good prognosis in infiltrating ductal carcinoma of breast. , 2013, Indian journal of cancer.

[21]  A. Neugut,et al.  Breast cancer characteristics and HIV among 1,092 women in Soweto, South Africa , 2013, Breast Cancer Research and Treatment.

[22]  J. Cutrell,et al.  Non-AIDS-defining Cancers Among HIV-Infected Patients , 2013, Current HIV/AIDS Reports.

[23]  A. Justice,et al.  HIV infection, aging, and immune function: implications for cancer risk and prevention , 2012, Current opinion in oncology.

[24]  R. Koup,et al.  CD8+ T cells in preventing HIV infection and disease , 2012, AIDS.

[25]  Abhi Shelat,et al.  One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.

[26]  D. Hazuda,et al.  HIV-1 antiretroviral drug therapy. , 2012, Cold Spring Harbor perspectives in medicine.

[27]  L. Collins,et al.  Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer , 2012, Breast Cancer Research and Treatment.

[28]  D. Talwar,et al.  A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. , 2011, European journal of cancer.

[29]  Shuntai Zhou,et al.  Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. , 2011, The Lancet. Infectious diseases.

[30]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Goedert,et al.  Cancer burden in the HIV-infected population in the United States. , 2011, Journal of the National Cancer Institute.

[32]  R. Palmqvist,et al.  Colorectal cancer prognosis depends on T-cell infiltration and molecular characteristics of the tumor , 2011, Modern Pathology.

[33]  S. Franceschi,et al.  Cancer incidence in people with AIDS in Italy , 2010, International journal of cancer.

[34]  Achim Zeileis,et al.  Generalized Maximally Selected Statistics , 2008, Biometrics.

[35]  P. Sullivan,et al.  Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.

[36]  N. Probst-Hensch,et al.  Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy , 2008, AIDS.

[37]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[38]  Teruhiko Yoshida,et al.  Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications. , 2006, International journal of oncology.

[39]  A. Tyznik,et al.  Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells , 2006, Nature.

[40]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[41]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[42]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[43]  Gavin P Dunn,et al.  Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. , 2006, Advances in immunology.